Biotech & AI drug discoveryNature Medicine

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial

Nature Medicine reports 5-year survival and biomarker analyses from the phase 3 RELATIVITY-047 trial, which compared relatlimab plus nivolumab against nivolumab alone in advanced melanoma. Specific outcome data are not provided in the available context.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-24T00:00:00+00:00

Published here2026-10-25T21:52:30+00:00

Original source

Nature Medicine

Media report · consult original reporting

Read the original ↗https://www.nature.com/articles/s41591-026-04756-1

Original headline

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.